Evidence that the high incidence of treatment failures in Indian kala- azar is due to the emergence of antimony-resistant strains of Leishmania donovani

Journal of Infectious Diseases

Volumn 180, Issue 2, 1999, Pages 564-567

  Lira, Rosalia ^a   Sundar, Shyam ^c   Makharia, A ^c   Kenney, Richard ^b   Gam, Albert ^b   Saraiva, Elvira ^a,d   Sacks, David ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c BANARAS HINDU UNIVERSITY   (India)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY; ANTIMONY GLUCONATE;

ADOLESCENT; ADULT; AMASTIGOTE; ANIMAL CELL; ARTICLE; CHILD; DRUG SENSITIVITY; FEMALE; HUMAN; INCIDENCE; LEISHMANIA DONOVANI; LEISHMANIASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; TREATMENT FAILURE;

ADOLESCENT; ADULT; ANIMALS; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; CHILD; DRUG RESISTANCE; FEMALE; HUMANS; INDIA; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; SPLEEN; TREATMENT FAILURE;

EID: 0033509735     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314896     Document Type: Article

References (15)

1. 1. Monograph on Kala azar incidence in Bihar (1985 1991; 1991 1996). Office of the Chief Malaria Officer, Bihar Directorate of Health Services, Patna, Bihar.
2. 2. Thakur CP. Epidemiological, clinical and therapeutic features of Bihar kalaazar (including post kala-azar dermal leishmaniasis). Trans R Soc Trop Med Hyg 1984; 78:391-8.
3. 3. Thakur CP, Kumar M, Kumar P, Mishra BN, Pandey AK. Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study. Br Med J (Clin Res Ed) 1988;296:1557-61.
4. 4. Thakur CP, Pandey AK, Kumar N, Kumar P, Hassan S, Narain S, Roy RK. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishnianiasis in Bihar, India, justify its continued use as a first line drug? An observational study of 80 cases. Ann Trop Med Parasitol 1998;92:561-9.
5. 5. Sundar S, Treatment of visceral leishmaniasis current status. J Assoc Physicians India 1997;45:640-5.
6. 6. Sundar S, Singh VP, Sharma S, Makharia MK, Murray H. Response to interferon-γ plus pentavalent antimony in Indian visceral leishmaniasis. J Infect Dis 1997; 176:1117-9.
7. 7. Mishra M, Biswas UK, Jha AM, Khan AB. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet 1994; 344:1599-600.
8. 8. Jackson JE, Tally JD, Ellis WY, et al. Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania ssp. from patients unresponsive to pentavalent antimony therapy. Am J Trop Med Hyg 1990; 43:464-80.
9. 9. Grogl M, Thomason TN, Franke ED. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am J Trop Med Hyg 1992; 47:117-26.
10. 10. Berman JD, Lee LS. Activity of antileishmanial agents against amastigotes in human monocyte-derived macrophages and in mouse peritoneal macrophages. J Parasitol 1984; 70:220-5.
11. 11. Ibrahim ME, Hag-Ali M, El-Hassan, Theander TG, Kharazmi A. Leishmania resistant to sodium stibogluconate: drug-associated macrophage-dependent killing. Parasitol Res 1994;80:569-74.
12. 12. Faraut-Gambarelli F, Piarroux R, Deniau M, et al. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob Agents Chemother 1997;41:827-30.
13. 13. Borst P, Ouellette M. New mechanisms of drug resistance in parasitic protozoa. Annu Rev Microbiol 1995;49:427-60.
14. 14. Roberts WL, Berman JD, Rainey MP. In vitro antileishmanial properties of tri and pentavalent antimonial preparations. Antimicrob Agents Chemother 1995; 39:1234-9.
15. 15. Ephros M, Waldman E, Zilberstein D. Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigoles and axenically grown amastigotes. Antimicrob Agents Chemother 1997; 41:1064-8.